A clinical trial of gene therapy for chronic pain
- PMID: 19818042
- PMCID: PMC3032602
- DOI: 10.1111/j.1526-4637.2009.00720.x
A clinical trial of gene therapy for chronic pain
Abstract
The first human trial of gene therapy for chronic pain, a phase 1 study of a nonreplicating herpes simplex virus (HSV)-based vector engineered to express preproenkephalin in patients with intractable pain from cancer, began enrolling subjects in December 2008. In this article, we describe the rationale underlying this potential approach to treatment of pain, the preclinical animal data in support of this approach, the design of the study, and studies with additional HSV-based vectors that may be used to develop treatment for other types of pain.
References
-
- Schug S, Gandham N. Opioids: Clinical Use. In: McMahon SB, Koltzenburg M, editors. Textbood of Pain. Elsevier; 2006. pp. 443–458.
-
- Dickenson AH, Kieffer BL. Opiates: Basic Mechanisms. In: McMahon SB, Koltzenburg M, editors. Textbook of Pain. Elsevier; 2006.
-
- Roizman B, Knipe DM. Herpes Simplex Viruses and Their Replication. In: Knipe DM, Howley PM, editors. Fields Virology. Philadelphia: Lippincott Williams & Wilkins; 2001. pp. 2399–2460.
-
- Wolfe D, Goins WF, Yamada M, Moriuchi S, Krisky DM, Oligino TJ, et al. Engineering herpes simplex virus vectors for CNS applications. Exp Neurol. 1999;159:34–46. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
